Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe

Diversifies Mylan Further Ahead Of Viatris

Executive Summary

With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.

You may also be interested in...



Exclusive: FTC Expected To Make Mylan-Upjohn Announcement Today

Almost 500 days after the transaction was first announced, Viatris, the proposed combination of Mylan and Pfizer’s Upjohn, is set to receive word from the US Federal Trade Commission, representing the last major obstacle to getting the deal over the line.

Mylan And Upjohn Combination Takes Key Step To Completion

Shortly after agreeing to divest three mature Upjohn brands in Australia, Mylan and the Pfizer off-patent and mature brands unit have stepped closer to merging into Viatris, bagging another key regulatory approval that had been in the works for several months.

Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now

Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel